Cancer patients and the Internet: a survey of the 'Quality of Life' Working Groups of the Arbeitsgemeinschaft für Internistische Onkologie and the Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie.

BACKGROUND: Patient-reported outcomes, such as quality of life (QoL) assessment, are becoming more important as endpoint in clinical trials and for decision making regarding new anticancer product approvals. Nevertheless, numerous obstacles exist regarding the implementation of QoL assessment in the daily practice of medical oncologists. Regular, computerized or internet home-based QoL assessments could be a step forward. METHODS: Using a 15-item paper questionnaire, we conducted a survey among 1580 cancer patients regarding their willingness to use internet QoL assessment, and collected personal data and information about current disease and performance status. RESULTS: Younger patients (i.e. ≤65 years) significantly more often had internet access (78% versus 36%; χ(2) test, p < 0.001). Moreover, the availability of internet access correlated with higher education levels. 55% of all polled patients are willing to use an internet-based QoL assessment tool, regardless of the type of internet access, whereas almost two-thirds (n = 600; 65%) of patients with their own internet access would be willing to use it for providing statements about QoL. Of these, especially younger patients in good health status with higher education degrees indicated their willingness to use such tools. CONCLUSION: These data may serve as a basis for identifying patient groups willing to participate in pilot projects to evaluate the implementation of internet-based regular assessment of QoL in cancer.

The delineation of target volumes for radiotherapy of lung cancer patients.

PURPOSE: Differences in the delineation of the gross target volume (GTV) and planning target volume (PTV) in patients with non-small-cell lung cancer are considerable. The focus of this work is on the analysis of observer-related reasons while controlling for other variables. METHODS: In three consecutive patients, eighteen physicians from fourteen different departments delineated the GTV and PTV in CT-slices using a detailed instruction for target delineation. Differences in the volumes, the delineated anatomic lymph node compartments and differences in every delineated pixel of the contoured volumes in the CT-slices (pixel-by-pixel-analysis) were evaluated for different groups: ten radiation oncologists from ten departments (ROs), four haematologic oncologists and chest physicians from four departments (HOs) and five radiation oncologists from one department (RO1D). RESULTS: Agreement (overlap > or = 70% of the contoured pixels) for the GTV and PTV delineation was found in 16.3% and 23.7% (ROs), 30.4% and 38.6% (HOs) and 32.8% and 35.9% (RO1D), respectively. CONCLUSION: A large interobserver variability in the PTV and much more in the GTV delineation were observed in spite of a detailed instruction for delineation. The variability was smallest for group ROID where due to repeated discussions and uniform teaching a better agreement was achieved.

Palliative total skin electron beam therapy (TSEBT) for advanced cutaneous T-cell lymphoma.

Our aim was to analyze the effectiveness of palliative total skin electron beam therapy (TSEBT) in the management of advanced cutaneous T-cell non-Hodgkin's lymphoma (CTCL). Eighteen patients (median age 59 years) with advanced and therapy-refractory CTCL in stages IIB-IV were treated with TSEBT for the first time. The most common histological subtype was Mycosis fungoides (72%). All patients suffered from lymphoma-associated symptoms. Median daily fractions of 1 Gy were administered up to a median total dose of 25 Gy. The median follow-up period was 11 months. Nine patients (50%) achieved a complete response and seven patients (39%) had a limited response. The actuarial one-year progression-free survival was 24%. Four patients (22%) had continuing remission over a median period of six months. Lymphoma associated symptoms were improved in 16 patients (89%). The median overall survival after receiving TSEBT was 12 months, resulting in an actuarial one-year overall survival of 48%. Treatment related acute effects (grade 1 or 2) were observed in all patients during radiation therapy. Transient grade 3 epitheliolyses developed in five patients (28%), late skin effects (grade 1 and 2) in 16 patients (89%), and hypohidrosis was seen in six patients (33%). We conclude that TSEBT is a very efficient and tolerable palliative treatment for patients with advanced CTCL.

Temozolomide combined with irradiation as postoperative treatment of primary glioblastoma multiforme. Phase I/II study.

BACKGROUND AND PURPOSE: The role of radiochemotherapy in the treatment of primary glioblastoma multiforme is still discussed controversially. To evaluate the feasibility and toxicity of irradiation and concomitant administration of 50 mg/m(2) temozolomide in patients with primary malignant glioma, this phase I/II study was conducted. PATIENTS AND METHODS: 53 Patients with histologically confirmed WHO grade IV malignant glioma were enrolled into the study. All patients were treated with radiation therapy up to a total dose of 60 Gy using conventional fractionation of 5 x 2.0 Gy/week. Temozolomide was administered orally each therapy day at a dose of 50 mg/m(2). RESULTS: Prior to radiochemotherapy, complete resection (n = 14), subtotal resection (n = 22) or a biopsy (n = 17) of the tumor was performed. The median time interval between surgery and radiochemotherapy was 21 days. Treatment-related toxicity was very mild. Acute toxicity > grade 2 was observed in one patient who developed grade 4 hemotoxicity. Minor side effects of chemotherapy included nausea and vomiting. No severe late effects were observed. Median progression-free and overall survival were 8 and 19 months, respectively. The overall survival rate was 72% at 1 and 26% at 2 years. Age and extent of surgery significantly influenced survival. CONCLUSION: The combination of temozolomide plus radiation therapy is feasible and safe in terms of toxicity. Overall survival times were relatively long compared to survival times reported for radiotherapy alone. The application of 50 mg/m(2) of temozolomide can be performed throughout the whole time course without interruption due to side effects and might largely contribute to the prolonged overall survival. Further evaluation is warranted as to which dose of temozolomide is optimal with regard to tumor response and toxicity.

Influence of irradiated volume on ureteral injury after intraoperative radiation therapy: experimental study in dogs.

PURPOSE: To investigate the role of irradiated volumes at intraoperative radiation therapy in the development of ureteral injury in dogs. MATERIALS AND METHODS: Sixteen beagle dogs were randomized to receive 30 Gy of intraoperative radiation therapy in the right ureter. Lead shielding ensured that different volumes were irradiated. Six dogs received a 4 x 12-cm field, five dogs a 4 x 8-cm field, and five dogs a 4 x 4-cm field. Follow-up included magnetic resonance (MR) imaging, clinical examination, and resting sequential renography. Twelve months after irradiation, the animals were killed, and autopsy was performed. Functional outcome was defined as MR imaging and renography findings and was evaluated statistically by using the Cochran-Armitage test at a.05 significance level. RESULTS: Twelve months after therapy, ureteral obstruction with consecutive hydronephrosis of the right kidney was observed in four of six animals that received the largest volume of irradiation. Two dogs that received the medium volume developed ureteral obstruction. None of the five dogs that received the smallest volume showed abnormal findings (P <.05). The irradiated parts of the ureters in all dogs showed abnormal histopathologic findings, such as fibrosis. CONCLUSION: The probability of ureteral obstruction following intraoperative radiation therapy increases with the irradiated partial volume of the ureter.

The electronic portal imaging system Siemens Beamview Plus versus the conventional verification films CEA-TVS and DuPont COL-7. A critical appraisal of visual image quality.

AIM: The aim of this study was the validation of the visual image quality of electronic portal imaging devices (EPID) and conventional verification films from the point of view of the end-viewers of portal films, the radiotherapists. MATERIAL AND METHODS: The verification image was represented in two different forms, viz. an electronic portal image employing Siemens Beamview Plus (on a computer monitor) and two different portal films using the conventional verification films CEA-TVS and DuPont CQL-7 (on a negatoscope). A total of 270 image sets (simulation film and portal image) were evaluated by each radiotherapist, evaluation extending to 90 sets of each type of verification film. Each set was evaluated by three specialists in radiotherapy examining subjective visual image quality whereby the following aspects served as evaluation criteria: contrast, artifacts, determination of actual radiation field edge position, anatomical structures and main structural feature for the determination of treatment field position. In addition, the anatomical structures employed for visual feature correlation between reference and portal films were classified according to their importance. RESULTS: In general the electronic portal image was rated significantly "visible" or better. Only the evaluation of artifacts showed an appreciable disadvantage for electronic portal imaging caused by physical artifacts due to radiographic technique and data processing aspects peculiar to the Siemens Beamview Plus 1.1. and also caused by different image processing tools reducing physical artifacts and enhancing the visibility of anatomical structures and likewise of anatomical artifacts (e.g. intestinal gas). By calculating the Spearman correlation coefficient to detect a possible relationship between the different criteria of subjective visual image quality, the research demonstrated that artifacts when limited to a tolerable proportion had no significant impact on the other criteria. CONCLUSIONS: As data of EPIDS are digital, images can be postprocessed and enhanced in a wide variety of ways. Using this tool the electronic portal imaging device provides images that, in terms of visual image quality, are at least comparable to the two evaluated types of radiographic films and also have the added advantage that such images are stored and can be transferred electronically being presupposition for digital patient documentation.

[Lung dose depending on exact patient positioning during total body irradiation (TBI). Isoeffectiveness considerations to assess the risk of interstitial pneumonia after TBI]. / Lungendosis in Abhängigkeit von der Lagerungsgenauigkeit bei Ganzkörperbestrahlungen (TBI). Isoeffektivitätsüberlegungen zur Einschätzung des Risikos einer interstitiellen Pneumonitis nach Ganzkörperbestrahlung.

PURPOSE: In this case report, we studied the effect of patient's movements on total lung dose during total body irradiation (TBI). The dose-effect relationship regarding the development of interstitial pneumonitis and the problem of defining a threshold value are discussed. Based on considerations about the isoeffects we calculated the pneumonitis risk in dependence of increasing lung dose. PATIENTS AND METHOD: We calculated dose-volume histograms of the lung for defined lateral deviations (0-3 cm) from the isocenter. Total dose was 12 Gy, given in six fractions over 3 days. Lung shields were used after a total dose of 9 Gy. Lung shields were transferred into the Helax-TMS planning system to quantify the influence of lateral deviation to lung dose. RESULTS: The child's lateral deviation amounted up to 3 cm. Median dose of the whole lung amounted up to 11.64 Gy depending on lateral deviation. DISCUSSION: In TBI, the lung limits the total dose. To estimate the risk of radiation pneumonitis, we calculated the isoeffective lung dose of our TBI regime for a fractionation scheme of 2 Gy daily using a formalism of van Dyk. The increase of median lung dose from 9.76 to 11.64 Gy would isoeffectively correspond to the increase from 19 Gy (no deviation) to 20.9 Gy (3 cm lateral deviation) with conventional fractionation. According to Burman, a pneumonitis risk of approximately 20% could be expected. CONCLUSION: With an estimated pneumonitis risk of approximately 20%, in indication for irradiation in general anesthesia seems to be reasonable. This is practicable in cooperation with radiation oncologists, anesthesists and pediatricians and should be included into therapeutic concepts.